Navigation Links
Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
Date:6/3/2011

QUEBEC CITY, June 3, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that Martin Driscoll has been appointed as chief executive officer.  With a solid foundation established at Asmacure, Mr. Driscoll will lead the company as it progresses its lead compound, a potential new treatment for asthma with a novel mechanism-of-action, further in clinical development.  Mr. Driscoll will be supported by the Asmacure team, including the company's founder and chief medical officer Dr. Yvon Cormier.  Dr. Luc Vachon, president and former CEO of Asmacure, will be departing the company to pursue other business ventures; however, he will remain actively involved with Mr. Driscoll and the company during a transitional period over the next few months.      

Mr. Driscoll has more than 30 years experience in the pharmaceutical industry, including senior roles in general management, commercial operations and business development for both privately held and publicly traded life science companies.  He led the commercialization of several successful therapeutic products, the direct negotiation of multiple transactions, licensing and M&A and the successful submission of multiple major product regulatory filings.  

Prior to being elected CEO of Asmacure, Mr. Driscoll was CEO and a director of Javelin Pharmaceuticals, Inc., a publicly traded company focused on the development of acute care pain products, from March 2008 until July 2010, at which point he led the successful merger of the company with Hospira, Inc.  Prior to his role with Javelin, Mr. Driscoll held senior managerial roles at Schering-Plough Corporation, ViroPharma, Inc. and Reliant Pharmaceuticals.  During his tenure at Schering-Plough, Mr. Driscoll spent a significant amount of time as g
'/>"/>

SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
2. Omeros Appoints David A. Mann to its Board of Directors
3. RainDance Technologies Appoints Olex Vice President, System Development
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
6. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
7. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
8. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
9. UltraShape Appoints Assaf Eyal as President & CEO
10. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
11. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... and TEL AVIV, Israel , May ... the "Company") (NYSE MKT: NSPR), a leader in embolic protection ... Company,s President and Chief Executive Officer, and Craig ... in the Benchmark Company, LLC One-on-One Investor Conference on Thursday ... Ave., Milwaukee, WI. The ...
(Date:5/24/2013)... Oklahoma City, OK (PRWEB) May 24, 2013 ... handful of casualties. And following its ravage, the mayor of ... room bill for new houses, said a report from cnn.com. ... offered the tornado victims complimentary Molderizer and Safe Shield to ... according to the report published on May 22, 2013, caused ...
(Date:5/23/2013)... Mich. Every day, their baby stopped breathing, his ... his lungs. April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good ... Gionfriddo, about her now 20-month-old son, Kaiba. "At that ... would take it and run with it." , They ...
(Date:5/23/2013)... Graphite Metallizing Corporation announces a series ... stainless steel pillow blocks. This series combines the ... application and installation versatility of pillow blocks. , ... exceptionally well when submerged in water, water-soluble chemicals ... acids, alkalies, hydrocarbons, black liquor, and liquid gases. ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 2Graphite Metallizing Now Offers GRAPHALLOY® Stainless Steel Pillow Blocks for Success in Submersible Applications 3
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... the Company,s workforce, resulting in a reduction in staff of ... due to the Complete Response Letter it received from the ... on January 31, 2011 regarding the New Drug Application (" ...
... ERES ) announced today that it will release its ... March 1, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
... HIGHLIGHTS:2010 Results (all percentages are to comparable periods in ... million, a new quarterly high. Q4 sales grew by 2% and ... 2010 sales increased 6% and 5% on a reported and currency ... EPS was $0.76. Excluding restructuring costs of $0.07, adjusted Q4 2010 ...
Cached Biology Technology:Orexigen® Therapeutics Announces Corporate Realignment 2Orexigen® Therapeutics Announces Corporate Realignment 3ERT Reports Fourth Quarter and Full Year 2010 Operating Results on March 1, 2011 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13
(Date:5/24/2013)... 24, 2013 A frequently expressed concern in the ongoing ... fresh vegetables, especially those that are nutrient dense. ... and Beans Provide Most Nutrients Per Penny," published in ... are one of the best nutritional values in the ... per penny than most other raw vegetables and delivering ...
(Date:5/24/2013)... detection and destruction by the immune system. Stimulation of ... however, there are many factors that cause the immune ... immune cells that function to suppress the immune system ... Clinical Investigation , researchers led by Ronald Levy at ... tumors express proteins that can be targeted with therapeutic ...
(Date:5/24/2013)... against Alzheimer,s disease, scientists have focused among other factors ... After all, it is the accumulation of A-beta that causes ... point for the formation of A-beta is APP. Alessia Soldano ... the function of APPL the fruit-fly version of APP ... Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ensures ...
Breaking Biology News(10 mins):New research shows that potatoes provide one of the best nutritional values per penny 2A new strategy required in the search for Alzheimer's drugs? 2
... and diesel with plant-based bio fuels is crucial to curb climate ... and some of the methods result in bio fuels that are ... from the University of Copenhagen shows that it is possible to ... single drop. This promises cheaper, faster and above all safer development ...
... usually progresses in small steps, but on rare occasions, ... produces a ,great leap forward., An international team of ... Joseph Ecker, report one such leap in the July ... their mapping and early analyses of thousands of protein-to-protein ...
... 29, 2011Intravenous delivery of cold fluids to reduce body ... outcomes may not be as effective in children as ... in Therapeutic Hypothermia and Temperature Management , a ... article is available free online at www.liebertpub.com/ther ...
Cached Biology News:Computational chemistry shows the way to safer biofuels 2Scientists take a giant step for people -- with plants! 2Scientists take a giant step for people -- with plants! 3Scientists take a giant step for people -- with plants! 4
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
ANTI S. ENT TOX BC2D...
... Anti-Major DNA-binding protein(DBP). Protein size: ... NP_001343 ELISA titre using peptide ... conditions for Western Blot: 1.0g/ml ... and HRP conjugated anti-Rabbit IgG should be ...
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Biology Products: